Collegium Pharmaceutical, Inc. Lease, Cost
Collegium Pharmaceutical, Inc. (COLL) reported Lease, Cost of $5.96 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-26
- Collegium Pharmaceutical, Inc. lease, cost for the quarter ending 2019-12-31 was $793.00K.
- Collegium Pharmaceutical, Inc. lease, cost for the quarter ending 2019-09-30 was $671.00K.
- Collegium Pharmaceutical, Inc. lease, cost for the quarter ending 2019-06-30 was $497.00K.
- Collegium Pharmaceutical, Inc. lease, cost for the quarter ending 2019-03-31 was $520.00K.
- Collegium Pharmaceutical, Inc. lease, cost for fiscal 2025 was $5.96M, a 55.60% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. lease, cost for fiscal 2024 was $3.83M, a 15.50% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. lease, cost for fiscal 2023 was $3.32M, a 6.01% increase from fiscal 2022.
- Collegium Pharmaceutical, Inc. lease, cost for fiscal 2022 was $3.13M, a 1.29% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $5.96M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $3.83M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $3.32M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $3.13M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $3.09M 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $2.95M 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $793.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.46M derived: sum of 2 quarters · filed 2022-02-24 | $1.96M derived: sum of 3 quarters · filed 2022-02-24 | $2.48M 10-K · filed 2022-02-24 |
| 2019-09-30 | $671.00K 10-Q · filed 2019-11-06 | $1.17M derived: sum of 2 quarters · filed 2019-11-06 | $1.69M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $497.00K 10-Q · filed 2019-08-07 | $1.02M 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $520.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |